GREATER CANNABIS TO BEGIN CLINICAL STUDY OF CBD ABSORPTION THROUGH ITS MULTIFUNCTIONAL, MULTILAYER INTRA-ORAL DRUG DELIVERY TECHNOLOGY
01 avr. 2019 10h25 HE
|
The Greater Cannabis Company, Inc.
Study Continues To Expand, Drive Commercialization Of Company’s Eluting Patch Technology To LPs, Consumer Product And Pharmaceutical Companies BALTIMORE, MD, April 01, 2019 (GLOBE NEWSWIRE)...
IntelGenx Reports Fourth Quarter and Full-Year 2018 Financial Results
22 mars 2019 16h05 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, March 22, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth quarter...
CORRECTION - IntelGenx to Report Fourth Quarter and Full-Year 2018 Financial Results on March 22, 2019 – Conference Call to Follow on March 25, 2019
18 mars 2019 17h35 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, March 18, 2019 (GLOBE NEWSWIRE) -- In a release issued under a similar headline earlier today by IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT), please note that...
IntelGenx to Report Fourth Quarter and Full-Year 2018 Financial Results on March 25, 2019 – Conference Call to Follow
18 mars 2019 16h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, March 18, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) today announced that it will release its fourth quarter and full year 2018...
IntelGenx Announces Montreal’s Douglas Mental Health University Institute as Ninth Montelukast VersaFilm™ Phase 2a Clinical Trial Site
14 févr. 2019 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 14, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that, subject to final research...
IntelGenx Granted Japanese Patent for RIZAPORT® VersaFilm™
11 févr. 2019 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 11, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has received a Decision...
IntelGenx Strengthens Senior Management Team
07 févr. 2019 16h00 HE
|
IntelGenx Technologies Corp.
SAINT-LAURENT, Québec, Feb. 07, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT), today announced that it has strengthened its management team with the...
IntelGenx Facility Undergoes U.S. FDA Pre-Approval Inspection Related to RIZAPORT® NDA
30 janv. 2019 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Jan. 30, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that the U.S. Food and Drug...
IntelGenx Provides Update on Phase 2a Montelukast VersaFilm™ Clinical Trial
23 janv. 2019 08h00 HE
|
IntelGenx Technologies Corp.
Eight Alzheimer’s Disease Patients Randomized to Date with Two Additional Sites Expected SAINT LAURENT, Quebec, Jan. 23, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT)...
IntelGenx Provides Update on Cannabis-Infused VersaFilm™ Program Following Recently Proposed Amendments to the Cannabis Act
14 janv. 2019 08h00 HE
|
IntelGenx Technologies Corp.
Working with partner Tilray®, IntelGenx aims to launch oral film products in late-2019 SAINT LAURENT, Quebec, Jan. 14, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT)...